CTOs on the Move

Vigil Neuroscience

www.vigilneuro.com

 
Vigil Neuroscience is the world`s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain`s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vigilneuro.com
  • One Broadway Suite 07-300
    Cambridge, MA USA 02142
  • Phone: 857.254.4445

Executives

Name Title Contact Details

Funding

Vigil Neuroscience raised $50M on 12/08/2020

Similar Companies

Halcyon Rehabilitation

Halcyon Rehabilitation enhances the quality of life in the community we service through top tier Physical Therapy, Occupational Therapy and Speech Language Pathology focused on long term care facilities. Our population focused programs allow us to assi...

HospiScript Services

HospiScript Services, LLC is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Headstrong Project

Headstrong provides cost-free, barrier-free, stigma-free mental health treatment for veterans and their families.

IVX Health

Our local centers provide infusion care such as Remicade, Ocrevus, and Entyvio and injections like Xolair and Fasenra for patients with ongoing conditions.

Trimel Pharmaceuticals

Trimel Pharmaceuticals Corporation is a Canadian specialty pharmaceutical company focused on bringing innovative products to market that improve the patient experience and produce strong investor returns. The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry powder inhaler/nasal dispersion system (“TriVair™”). The Corporation is focussing its present efforts on the development and application of these technologies for therapeutic categories such as (a) male hypogonadism (“low testosterone” or “Low-T”) and (b) female orgasmic disorder. Additionally, the Corporation owns the Canadian rights to ESTRACE® and is overseeing its distribution and marketing in Canada. The Corporation’s present drug delivery technology platforms are intended to create products that are expected to be innovative, safer, possibly more effective, easier to use and more practical than competitive products on the market.